Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Liver Diseases

Free Subscription 03.08.2026 1 Am J Pathol 2 Anticancer Res 3 Biochem Biophys Res Commun 1 BMC Cancer 1 Cancer 1 Cancer Res 14 Clin Res Hepatol Gastroenterol 1 Endoscopy 5 Gut 1 J Clin Oncol 2 J Gastroenterol 5 J Hepatol 1 J Pediatr Surg 1 Oncogene 1 PLoS One 1 Radiol Imaging Cancer 1 Transplant Proc 3 Transplantation

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Pathol

1. YU YP, Liu S, Singhi A, Luo JH, et al
   Fusion Gene Detection Enhances Clinical Outcome Prediction of Hepatocellular Carcinoma Through Machine Learning Analyses.
   Am J Pathol. 2026 Jul 28:S0002-9440(26)00199.
   PubMed         Abstract available
   
   

   
   Anticancer Res

2. UCHIHARA N, Tamaki N, Marusawa H, Urawa N, et al
   Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma.
   Anticancer Res. 2026;46:4443-4452.
   PubMed         Abstract available
   
   
3. SAKAI H, Goto Y, Fukutomi S, Arai S, et al
   Minimally Invasive Versus Open Liver Resection for HCC in the Posterosuperior Segments: A Propensity Score-matched Study.
   Anticancer Res. 2026;46:4735-4744.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

4. ZHOU T, Shen L, Ma Y, Mo S, et al
   SMURF1-mediated EFEMP1 ubiquitination reverses the resistance of HCC cells to sorafenib by promoting ferroptosis.
   Biochem Biophys Res Commun. 2026;830:154242.
   PubMed         Abstract available
   
   
5. FANG X, Liang Z, Zhang Z, Tao M, et al
   Corrigendum to "Natural exosome-like nanovesicles from Smilax China rhizome induce mitophagy-dependent ferroptosis in hepatocellular carcinoma via GPX4/ACSL4 axis" [Biochem. Biophys. Res. Commun. 800 (2026) 153270].
   Biochem Biophys Res Commun. 2026 Jul 29:154340. doi: 10.1016/j.bbrc.2026.154340.
   PubMed        
   
   
6. LI C, Ke J, Li X, Ji B, et al
   Nanotechnology-assisted thermal ablation for hepatocellular carcinoma: Focus on radiofrequency and microwave ablation.
   Biochem Biophys Res Commun. 2026;831:154269.
   PubMed         Abstract available
   
   

   
   BMC Cancer

7. MOSER C, Lang SA, Mori A, Hellerbrand C, et al
   Editorial expression of concern: NMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma (HCC) cells, and inhibits growth and vascularization in vivo.
   BMC Cancer. 2026;26:899.
   PubMed        
   
   

   
   Cancer

8. LAU-MIN KS, Wang J
   Where does histotripsy fit into hepatocellular carcinoma care?
   Cancer. 2026;132:e70547.
   PubMed         Abstract available
   
   

   
   Cancer Res

9. LI J, Ren Z, Yao J, Zhao Y, et al
   Mechanosensors Collaborate to Regulate DNA Damage Repair in Hepatocellular Carcinoma.
   Cancer Res. 2026 Jul 29. doi: 10.1158/0008-5472.CAN-25-4356.
   PubMed         Abstract available
   
   

   
   Clin Res Hepatol Gastroenterol

10. LIU Q, Zhang L, Wang Y, Li J, et al
    Effect of intermittent fasting on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease.
    Clin Res Hepatol Gastroenterol. 2026;50:102875.
    PubMed         Abstract available
    
    
11. KANGAS T, Plessier A, Ramier C, Elkrief L, et al
    Employment and work absenteeism in individuals living with a vascular liver disease: a European multicenter study.
    Clin Res Hepatol Gastroenterol. 2026;50:102876.
    PubMed         Abstract available
    
    
12. SUFFERT LC, Pergher EAB, de Abreu HS, Abreu ES, et al
    Burden and Distribution of Multidrug-Resistant Bacteria Among Hospitalized Patients with Cirrhosis: A Systematic Review and Meta-Analysis.
    Clin Res Hepatol Gastroenterol. 2026 Jun 30:102877.
    PubMed         Abstract available
    
    
13. REN R, Wang Z
    Safety and efficacy of hepatic arterial infusion chemotherapy combined with camrelizumab and apatinib for advanced hepatocellular carcinoma: A retrospective clinical analysis.
    Clin Res Hepatol Gastroenterol. 2026;50:102880.
    PubMed         Abstract available
    
    
14. KAGZI Y, Asif A, Wang Y, Fischer J, et al
    Evaluating performance of non-invasive tests for fibrosis detection in MASLD with Type 2 Diabetes Mellitus: Insights from VCTE-Based assessment.
    Clin Res Hepatol Gastroenterol. 2026;50:102879.
    PubMed         Abstract available
    
    
15. MA X, Huang C, Shi H, Wang Q, et al
    Clinical features of anti-gp210-positive, AMA-negative patients with abnormal liver function.
    Clin Res Hepatol Gastroenterol. 2026;50:102846.
    PubMed         Abstract available
    
    
16. LOWRY ADAMITIS SB, Karnsakul W
    Optimizing approach to liver biochemistry abnormalities in cystic fibrosis pediatrics: Balancing efficiency and risk-benefit.
    Clin Res Hepatol Gastroenterol. 2026;50:102849.
    PubMed         Abstract available
    
    
17. EL BOUKILI I, Habouzit V, Mohamed S, Casteillo F, et al
    Selective internal radiation therapy as a bridge to curative-intent surgery in bulky colorectal liver metastases.
    Clin Res Hepatol Gastroenterol. 2026;50:102851.
    PubMed         Abstract available
    
    
18. SCHMITZ SM, Grunwald BT, Tasdogan A, Heise D, et al
    Impact of Metabolic Liver Disease on Colorectal Cancer and Liver Metastases: Pathophysiology and Implications for Hepatobiliary Surgery.
    Clin Res Hepatol Gastroenterol. 2026 May 25:102853.
    PubMed         Abstract available
    
    
19. CHEN Z, Zhu W, Liu G, Yu B, et al
    Integrative Analysis of Genetic and Cellular Interactions Connecting Inflammatory Bowel Disease and Primary Biliary Cholangitis.
    Clin Res Hepatol Gastroenterol. 2026 Jul 14:102885.
    PubMed         Abstract available
    
    
20. WANG L, Chen J, Lou X, Liu J, et al
    Causes of death in patients diagnosed with liver metastasis: a population-based study.
    Clin Res Hepatol Gastroenterol. 2026;50:102883.
    PubMed         Abstract available
    
    
21. SUN K, Gao Q, Zhang C, Niu H, et al
    TACE-induced liver injury in hepatocellular carcinoma: mechanisms, prediction, and prevention in the era of gut microbiota and inflammasome research.
    Clin Res Hepatol Gastroenterol. 2026;50:102874.
    PubMed         Abstract available
    
    
22. FISCHER SE, van Ruijven B, Kerbert AJC, Fiocco M, et al
    Dipstick urinary chloride as a surrogate marker of urinary sodium in cirrhosis: a prospective multicenter pilot study.
    Clin Res Hepatol Gastroenterol. 2026 Jun 16:102871.
    PubMed         Abstract available
    
    
23. DIAZ I, Ahmad S, Souza M
    Primary hypobetalipoproteinemia as a specific etiology of steatotic liver disease: A meta-analysis.
    Clin Res Hepatol Gastroenterol. 2026;50:102863.
    PubMed         Abstract available
    
    

    
    Endoscopy

24. HU SS, Liu WH
    Contrast-harmonic endoscopic ultrasound-assisted endoscopic ultrasound-guided hepaticogastrostomy for minimally dilated intrahepatic ducts.
    Endoscopy. 2026 Jul 31. doi: 10.1055/a-2908-4930.
    PubMed        
    
    

    
    Gut

25. TAVABIE O, Crisp H, Griffiths C, Allen R, et al
    A patient-driven agenda for liver cirrhosis research.
    Gut. 2026 Jul 27:gutjnl-2026-339715. doi: 10.1136/gutjnl-2026-339715.
    PubMed        
    
    
26. YANG G, Gou L, Liu X, Xu C, et al
    Galectin-14, a primate-specific oncofetal protein, impairs anti-tumour immunity in hepatocellular carcinoma by driving elevated heparan sulphate modification.
    Gut. 2026 Jul 28:gutjnl-2026-338068. doi: 10.1136/gutjnl-2026-338068.
    PubMed         Abstract available
    
    
27. PIECHA F, Al Jawazneh A, Buescher G, Harberts A, et al
    Decompression of portal hypertension by transjugular intrahepatic portosystemic shunt reverses markers of gut barrier dysfunction and cirrhosis-associated immune dysfunction.
    Gut. 2026 Jul 30:gutjnl-2026-338318. doi: 10.1136/gutjnl-2026-338318.
    PubMed         Abstract available
    
    
28. YANG TC, Ha NB, Fan B, Barry F, et al
    Rate and clinical predictors of skeletal muscle loss in patients with cirrhosis.
    Gut. 2026 Jul 30:gutjnl-2026-339159. doi: 10.1136/gutjnl-2026-339159.
    PubMed         Abstract available
    
    
29. D'ALESSIO A, Wong CC
    Clonal evolution driving timing and sites of postsurgical recurrences in hepatocellular carcinoma.
    Gut. 2026 Jul 31:gutjnl-2026-339683. doi: 10.1136/gutjnl-2026-339683.
    PubMed        
    
    

    
    J Clin Oncol

30. LEVI ST, Barkun J, McCulloch P, Odisio BC, et al
    Histotripsy and the IDEAL Framework: A Clarion Call for the Responsible and Evidence-Based Application of New Technology.
    J Clin Oncol. 2026;44:2075-2078.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

31. FAN Z, Li L
    Comment on "Intestinal obstruction impairs the antitumor function of hepatic natural killer cells against colorectal cancer".
    J Gastroenterol. 2026 Jul 28. doi: 10.1007/s00535-026-02490.
    PubMed        
    
    
32. YASUDA K, Iida N, Takeshita Y, Masuo Y, et al
    Tofogliflozin alters amino acid metabolism in gut microbiota linked to hepatic transcriptomic signatures in MASLD.
    J Gastroenterol. 2026 Jul 30. doi: 10.1007/s00535-026-02488.
    PubMed         Abstract available
    
    

    
    J Hepatol

33. CHAN SL, Sangro B, Rimassa L
    The hepatocellular carcinoma wish list: Five aspirations for future care.
    J Hepatol. 2026 Jul 25:S0168-8278(26)02705-4. doi: 10.1016/j.jhep.2026.
    PubMed        
    
    
34. ENGELMANN C, Verma N, Qi T, Catharina Kerbert AJ, et al
    Corrigendum to "Development and validation of the A-TANGO organ failure score for acute-on-chronic liver failure in global cohorts" [J Hepatol 85 (2026) 91-105].
    J Hepatol. 2026 Jul 25:S0168-8278(26)02713-3. doi: 10.1016/j.jhep.2026.
    PubMed        
    
    
35. CASTILLO E, Felber M, Paule L, Juanola O, et al
    Non-selective beta-blockers reduce bacterial translocation by restoring gut barrier function during experimental cirrhosis.
    J Hepatol. 2026 Jul 28:S0168-8278(26)02747-9. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    
36. BHOORI S, Rivoltini L, Leoncini G, Sioli V, et al
    Revisiting rejection after immune checkpoint inhibitor exposure prior to liver transplantation for hepatocellular carcinoma: Reply to: "Rejection and perioperative management in liver transplantation following immune checkpoint inhibitor-based downsta
    J Hepatol. 2026 Jul 30:S0168-8278(26)02749-2. doi: 10.1016/j.jhep.2026.
    PubMed        
    
    
37. GUO Z, Zhao Q, Jia Z, Huang C, et al
    Corrigendum to: "A randomized-controlled trial of ischemia-free liver transplantation for end-stage liver disease" [J Hepatol 79 (2023) 394-402].
    J Hepatol. 2026 Jul 30:S0168-8278(26)02711-X. doi: 10.1016/j.jhep.2026.
    PubMed        
    
    

    
    J Pediatr Surg

38. TIAN Y, Chen X, Ye M, Xiao P, et al
    Prospective Comparison of Near-Infrared I and II Fluorescence Imaging for Intraoperative Navigation in Pediatric Hepatoblastoma Resection.
    J Pediatr Surg. 2026 Jul 30:163340. doi: 10.1016/j.jpedsurg.2026.163340.
    PubMed         Abstract available
    
    

    
    Oncogene

39. HUANG H, Huang C, Yang P, Xian S, et al
    The epigenetic KMT5C-HDAC1 axis promotes hepatocellular carcinoma stemness and progression through SERPINA4 repression and chromatin compaction.
    Oncogene. 2026 Jul 27. doi: 10.1038/s41388-026-03920.
    PubMed         Abstract available
    
    

    
    PLoS One

40. GU K, Kang TW, Shin J, Sinn DH, et al
    Prognostic factors in first-line atezolizumab-bevacizumab treatment of intermediate or advanced hepatocellular carcinoma.
    PLoS One. 2026;21:e0354176.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

41. SIDDIQI NS
    Intratumoral Therapy with or without Pulsed Electric Field Ablation for Hepatocellular Carcinoma: A Proof-of-Concept Study.
    Radiol Imaging Cancer. 2026;8:e269017.
    PubMed        
    
    

    
    Transplant Proc

42. MARIN-CASTRO P, Pinheiro RS, Waisberg DR, Arantes RM, et al
    Profile of Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma at a Brazilian High-Complexity Referral Center: Tumor Biology as a Predictor of Post-Transplant Recurrence.
    Transplant Proc. 2026 Jul 31:S0041-1345(26)00358.
    PubMed         Abstract available
    
    

    
    Transplantation

43. CALTHORPE LM, Lee C, Fenton C, Barron G, et al
    The Activity Measure for Postacute Care "6-Clicks" Basic Mobility Score is Associated with Pre- and Posttransplant Mortality in Hospitalized Patients with Cirrhosis.
    Transplantation. 2026 Jul 30. doi: 10.1097/TP.0000000000005855.
    PubMed         Abstract available
    
    
44. QUINTERO-BERNABEU J, Salcedo-Allende MT, Juamperez-Goni J, Mercadal-Hally M, et al
    Follow-up Liver Biopsy as a Tool for Tailoring Immunosuppressive Treatment in Pediatric Liver Transplantation.
    Transplantation. 2026 Apr 27. doi: 10.1097/TP.0000000000005721.
    PubMed         Abstract available
    
    
45. TANAKA T, Lai JC, Axelrod D
    Incorporating Model for End-stage Liver Disease Trajectories into Liver Allocation.
    Transplantation. 2026;110:e1687-e1694.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum